How can a policy foster local pharmaceutical production and still protect public health? Lessons from the health–industry complex in Brazil

References

• Abbott, F. (2017a). China policies to promote local production of pharmaceutical products and protect public health. Geneva: World Health Organization.
   Google Scholar
• Abbott, F. (2017b). Indian policies to promote local production of pharmaceutical products and protect public health. Geneva: World Health Organization.
   Google Scholar
• Acharya, T. (2007). Science and technology for wealth and health in developing countries. Global Public Health, 2(1), 53–63. doi: 10.1080/17441690600673833
   PubMedGoogle Scholar
• Agencia Brasil. (2016, October 19). Ministério anuncia R$ 6 bilhões em investimentos para produção de medicamentos.
   Google Scholar
• Agencia de Noticias da AIDS. (2012, July 2). Ministério da Saúde nega acesso a informações sobre contratos para fabricação de antirretrovirais, denuncia ABIA.
   Google Scholar
• Agencia Estado. (2009, July 7). Genérico do Efavirenz só sai em 2009.
   Google Scholar
• Bates, R. (2008). Local pharmaceutical production in developing countries: How economic protectionism undermines access to quality medicines. London: International Policy Network. Retrieved from Campaign for Fighting Diseases discussion paper no. 1.
   Google Scholar
• BBC Brazil. (2015, February 11). Farmacêuticas têm vitória com projeto de lei polêmico sobre biodiversidade. BBC Brazil.
   Google Scholar
• Brasil. (2003). Forum de competitividade da cadeia produtiva farmaceutica. Brasilia: Ministério do Desenvolvimento, Indústria e Comércio Exterior.
   Google Scholar
• Chaudhuri, S. (2007). The gap between successful innovation and access to its benefits: Indian pharmaceuticals. The European Journal of Development Research, 19(1), 49–65. doi: 10.1080/09578810601144293
   Google Scholar
• Chaves, C., Hasenclever, L., Serpa, C., Osorio-de-Castro, C., & Oliveira, M. (2015). Estratégias de redução de preços de medicamentos para aids em situação de monopólio no Brasil. Revista de Saude Publica, 49(86), 1–11.
   PubMedGoogle Scholar
• Diário do Comércio Industria e Serviços. (2014, December 14). Indústria farmacêutica quer mais transparência nos programas de parcerias do Governo.
   Google Scholar
• Di Tommaso, M., & Schweitzer, S. (Eds.). (2005). Health policy and high-tech industrial development: Learning form innovation in the health industry. Northampton: Edward Elgar Publishing.
   Google Scholar
• Dong, J., & Mirza, Z. (2016). Supporting the production of pharmaceuticals in Africa. Bulletin of the World Health Organization, 94, 71–72. doi: 10.2471/BLT.15.163782
   PubMed Web of Science ®Google Scholar
• Eckstein, H. (1975). Case study and theory in political science. In F. Greenstein, & N. Polsby (Eds.), Handbook of political science (pp. 79–117). Reading: Addison-Wesley Publishing Co.
   Google Scholar
• Falleti, T. (2010). Infiltrating the state: The evolution of health care reforms in Brazil, 1964–1988. In J. Mahoney, & K. Thelen (Eds.), Explaining institutional change: Ambiguity, agency, and power (pp. 38–62). New York/Cambridge: Cambridge University Press.
   Google Scholar
• Flynn, M. (2015). Pharmaceutical autonomy and public health in Latin America: State, society and industry in Brazil's AIDS program. New York: Routledge.
   Google Scholar
• Fonseca, E., Bastos, F., & Shadlen, K. (2017). Science, technology and health in Brazil: Incremental policy change and public health scholars as reform agents. Latin America Studies Association Annual Meeting, Lima, Peru.
   Google Scholar
• Fonseca, E., & Costa, N. (2015). Federalismo, Complexo Econômico da Saúde e Assistência Farmacêutica de Alto custo no Brasil. Ciência e Saúde Coletiva, 20(4), 1165–1176. doi: 10.1590/1413-81232015204.00562014
   PubMed Web of Science ®Google Scholar
• GSK. (2016, December 1). Acordo com o Ministério da Saúde permitirá acesso ao dolutegravir para tratamento de HIV dentro do Sistema Único de Saúde (SUS). GSK.
   Google Scholar
• Kaplan, W. (2011). Local production and access to medicines in low- and middle-income countries: A literature review and critical analysis. Geneva: World Health Organization.
   Google Scholar
• Kaplan, W., & Laing, R. (2005). Local production of pharmaceuticals: Industrial policy and access to medicines an overview of key concepts, issues and opportunities for future research. Washington, DC. Retrieved from World Bank HNP Discussion paper.
   Google Scholar
• Kostyanev, T., Bonten, M. J., O'Brien, S., & Goossens, H. (2015). Innovative medicines initiative and antibiotic resistance. The Lancet Infectious Diseases, 15(12), 1373–1375. doi: 10.1016/S1473-3099(15)00407-7
   PubMed Web of Science ®Google Scholar
• Mackintosh, M., Banda, G., Tibandebage, P., & Wamae, W. (Eds.). (2016). Making medicines in Africa: The political economy of industrializing for local health. New York: Palgrave Macmillan.
   Google Scholar
• Maxwell, J. (2005). Qualitative research design: An interactive approach (2nd ed.). London: Sage Publications.
   Google Scholar
• Ministério da Saúde. (2010). Mais saúde: direito de todos: 2008–2011 (4a edição). Brasília. Retrieved from Série C. Projetos, Programas e Relatórios.
   Google Scholar
• Ministério da Saúde. (2017). Relação de Parcerias para o Desenvolvimento Produtivo (PDP) segundo fases do processo. Retrieved October 27, from http://portalsaude.saude.gov.br/index.php/o-ministerio/principal/leia-mais-o-ministerio/581-sctie-raiz/deciis/l2-deciis/12090-parceria-para-o-desenvolvimento-produtivo-pdp
   Google Scholar
• Morgan, S., McMahon, M., & Greyson, D. (2008). Balancing health and industrial policy objectives in the pharmaceutical sector: Lessons from Australia. Health Policy, 87(2), 133–145. doi: 10.1016/j.healthpol.2008.01.003
   PubMed Web of Science ®Google Scholar
• Mujinja, P. G., Mackintosh, M., Justin-Temu, M., & Wuyts, M. (2014). Local production of pharmaceuticals in Africa and access to essential medicines: ‘urban bias’ in access to imported medicines in Tanzania and its policy implications. Globalization and Health, 10, 12. doi: 10.1186/1744-8603-10-12
   PubMed Web of Science ®Google Scholar
• New York Times. (2017, May 20). Brazil’s President assails his accuser as corruption scandal intensifie.
   Google Scholar
• Nunn, A. (2008). The politics and history of AIDS treatment in Brazil. New York: Springer.
   Google Scholar
• Nunn, A., da Fonseca, E., Bastos, F., & Gruskin, S. (2009). AIDS treatment in Brazil: Impacts and challenges. Health Affairs, 28(4), 1103–1113. doi: 10.1377/hlthaff.28.4.1103
   Web of Science ®Google Scholar
• Pan American Health Organization. (2017, June 12). OPAS/OMS, UNFPA e Ministério da Saúde orientam empresas farmacêuticas brasileiras a atuarem no mercado internacional. Retrieved from http://www.paho.org/bra/index.php?option=com_content&view=article&id=54303Aopasoms-unfpa-e-ministerio-da-saude-orientam-empresas-farmaceuticas-brasileiras-a-atuarem-no-mercado-internacional&catid=8443Abra-02-c-noticias&Itemid=455
   Google Scholar
• Panteli, D., & Busse, R. (2016). Pharmaceutical regulation in 15 European countries. Health Systems in Transition, 18(5), 1–125.
   Google Scholar
• Piovesan, M., & Labra, M. (2007). Institutional change and political decision making in the creation of the Brazilian National Health Surveillance Agency. Cadernos de Saúde Pública, 23(6), 1373–1382. doi: 10.1590/S0102-311X2007000600012
   PubMed Web of Science ®Google Scholar
• Revista Epoca. (2017, June 19). Por que o Brasil não tem penicilina?
   Google Scholar
• Russo, G., & Banda, G. (2015). Re-thinking pharmaceutical production in Africa; insights from the analysis of the local manufacturing dynamics in Mozambique and Zimbabwe. Studies in Comparative International Development, 50(2), 258–281. doi: 10.1007/s12116-015-9186-2
   Web of Science ®Google Scholar
• Sell, S., & Prakash, A. (2004). Using ideas strategically: The contest between business and NGO networks in intellectual property rights. International Studies Quarterly, 48, 143–175. doi: 10.1111/j.0020-8833.2004.00295.x
   Web of Science ®Google Scholar
• Shadlen, K., & Fonseca, E. (2013). Health policy as industrial policy: Brazil in comparative perspective. Politics and Society, 41(4), 561–587. doi: 10.1177/0032329213507552
   Web of Science ®Google Scholar
• Sidibé, M., Yongb, L., & Chan, M. (2014). Commodities for better health in Africa – time to invest locally. Bulletin of the World Health Organization, 92, 387–387A. doi: 10.2471/BLT.14.140566
   PubMed Web of Science ®Google Scholar
• United Nations. (2015). Transforming our world: The 2030 agenda for sustainable development. New York: United Nations.
   Google Scholar
• United Nations Conference on Trade and Development. (2011). Local production of pharmaceuticals and related technology transfer in developing countries: A series of case studies by the UNCTAD secretariat. Geneva: United Nations Conference on Trade and Development.
   Google Scholar
• Valor Economico. (2012, July 25). BNDES e sócios privados fazem aporte de R$ 35 milhões na Recepta Biopharma.
   Google Scholar
• Valor Economico. (2013a, September 03). Embrapii poderá receber recursos públicos para projetos de inovação. Valor Economico.
   Google Scholar
• Valor Economico. (2013b, September 27). Saída da Orygen não altera planos da Cristália. Valor Economico.
   Google Scholar
• Valor Economico. (2016). Libbs antecipa conclusão da fábrica e inicia produção piloto de biossimilar. Valor Economico.
   Google Scholar
• Vandergrift, M., & Kanavos, P. (1997). Health policy versus industrial policy in the pharmaceutical sector: The case of Canada. Health Policy, 41(3), 241–260. doi: 10.1016/S0168-8510(97)00036-5
   PubMed Web of Science ®Google Scholar
• World Health Organization. (1988). Guidelines for developing national drug policies. Geneve.
   Google Scholar
• World Health Organization. (2011). Local production for access to medical products: Developing a framework to improve public health. Geneva: World Health Organization.
   Google Scholar